- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04408378
Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients
Retrospective Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Covid-19 pneumonia is a spesific disease dispate its similarity to ARDS. There are nomorous of studies that MPV/PLT ratio can predict the mortality, morbidity and the progress of ARDS. Depending on the similarity of ARDS, MPV/PLT ratio might predict the clinical progress of Covid-19 pneumonia. We retrospectively recruited150 patients admitted to our institute -a tertiary center- with Covid-19 pneumonia to our study. Clinical based defining research, by March-May 2020, the patients over 18 years old who were in either intensive care or ward scanned retrospectively. The laboratory tests, chronic diseases , age and gender has been collected from the written resources and electronic data retrospectively.
the patients who are diagnosed with Covid*19 pneumonia will be divided into two groups. The ones in the ward will be considered as mild clinical course, and the ones in the intensive care unit will be considered as severe clinical course. there will be an additional non Covid individuals as a control group, which will consist 52 patients each. The ratio of MPV to PLT will be calculated using admission hemogrames of these groups, and the significance of the statistical differences on determining the prognosis of the disease will be discussed.
Gpower 3 for Mac Os (Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009). Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods, 41, 11491160.) was used for istatistical power analysis.It was done using ANOVA test between at least two independent groups. In order to provide enoughsample magnitude power, which is 0.8, it was calculated that each group should have 52 patients which makes at total of 156.
The normal distribution of data will be evaluated using Kolmogorov-Smirnov test. Parametric ones will be used in normal distrubitions, non-parametric ones will be uused in abnormal distrubitions. Between the independent groups, MPV/PLT ratio will be calculated using ANOVA test. Categoric data will be compared by Pearson ki square test and the p values less than 0.05 will be considered as significant.
we aim to have an opinion about Covid 19-pneomonia prognosis at the admission of hospital.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Gaziosmanpaşa
-
Istanbul, Gaziosmanpaşa, Turkey, 34255
- Recruiting
- Gaziosmanpaşa TREH
-
Contact:
- aygen türkmen, MD.prof.
- Phone Number: 1436 +902129453000
- Email: aygenturkmen@hotmail.com
-
Principal Investigator:
- zuhal çavuş, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients over 18 years old who hospitalized with diagnosis of Covid-19 pneumonia between march and may 2020
Exclusion Criteria:
- Under 18 years old patients
- Patients with heamolytic diaseses
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
mild pneumonia
The patients who has followed in the ward
|
We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
|
severe pneumonia
The patiens who has followed in the intensive care unit
|
We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
|
control group
patients who has not covid 19 pneumonia
|
We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
estimation of inflammatory changes in Covid 19 pneumonia by using MVP/PLT ratio
Time Frame: March-May 2020
|
İt has been studied that MPV/PLT ratio can show the cl inical couses of several diseases as well as ARDS.
we thought that we can identify the coronavirus pneumonia patients earlier, at admission of hospital by using the hemogrames.
|
March-May 2020
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Kim CH, Kim SJ, Lee MJ, Kwon YE, Kim YL, Park KS, Ryu HJ, Park JT, Han SH, Yoo TH, Kang SW, Oh HJ. An increase in mean platelet volume from baseline is associated with mortality in patients with severe sepsis or septic shock. PLoS One. 2015 Mar 5;10(3):e0119437. doi: 10.1371/journal.pone.0119437. eCollection 2015.
- Fei Y, Zhang H, Zhang C. The application of lymphocyte*platelet and mean platelet volume/platelet ratio in influenza A infection in children. J Clin Lab Anal. 2019 Nov;33(9):e22995. doi: 10.1002/jcla.22995. Epub 2019 Aug 16.
- Korniluk A, Koper-Lenkiewicz OM, Kaminska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 2019 Apr 17;2019:9213074. doi: 10.1155/2019/9213074. eCollection 2019.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronavirus Infection
-
The University of Hong KongHospital Authority, Hong KongCompletedNovel Coronavirus InfectionHong Kong
-
Affiliated Hospital to Academy of Military Medical...Beijing 302 HospitalUnknownNovel Coronavirus Infection PneumoniaChina
-
ProgenaBiomeDSCS CRORecruitingCOVID-19 | Coronavirus Infection | COVID | Corona Virus Infection | Coronavirus | Sars-CoV2 | Coronavirus-19 | Coronavirus 19United States
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
Concern GRANITSamara State Medical UniversityCompletedCoronavirus Infection COVID-19Russian Federation
-
D'Or Institute for Research and EducationUnknown
-
Chelsea and Westminster NHS Foundation TrustUnknownCOVID-19 | COVID-19 Infection | 2019 Novel Coronavirus InfectionUnited Kingdom
-
Institut National de la Santé Et de la Recherche...Recruiting
-
Kansas City Heart Rhythm InstituteTerminated
-
Universidade Federal de Sao CarlosTerminatedCoronavirus InfectionBrazil
Clinical Trials on observation of covid 19 pneumonia
-
Universidade do PortoCentro Hospitalar Lisboa Ocidental; Centro Hospitalar De São João, E.P.E.; Centro... and other collaboratorsActive, not recruitingQuality of Life | Coronavirus Infection | Morality | Rehospitalization | Long-term OutcomesPortugal
-
FMH College of Medicine and DentistryCompletedCOVID-19 PneumoniaPakistan
-
Tongji HospitalWithdrawnCOVID-19 | Endotracheal IntubationChina
-
University Hospital, ToulouseCompletedPneumonia, ViralFrance
-
Oslo University HospitalAge Labs ASRecruiting
-
Public health and reforms Center of Ministry of...World Health Organization; Ministry of Health of Azerbaijan RepublicRecruitingCovid19 | Vaccine RefusalAzerbaijan
-
Charles Drew University of Medicine and ScienceNot yet recruitingCOVID-19 | Pneumonia | Influenza | Meningitis | Vaccine Hesitancy | Varicella Zoster
-
xCuresCancer Commons; Genetic Alliance; LunaDNA; REDCap CloudCompleted
-
AstraZenecaCompleted
-
Hasanuddin UniversityChulalongkorn UniversityCompleted